Allied Minds and Bristol-Myers Squibb Advance Innovation in US Academia
Allied-Bristol Life Sciences will focus on converting university research into therapeutic candidates.
Allied Minds and Bristol-Myers Squibb Company formed Allied-Bristol Life Sciences LLC, a new jointly owned enterprise created to identify and foster research and preclinical development of biopharmaceutical innovations from leading university research institutions across the US.
Allied-Bristol Life Sciences will focus on efficiently and effectively converting discoveries from university research institutions into therapeutic candidates for clinical development and, ultimately, approved therapies that address serious diseases. For programs identified by the new enterprise, university researchers will be able to access Bristol-Myers Squibb's drug discovery research expertise and Allied Minds' financial and management experience.
"The innovations developed in US research institutions represent an important resource for scientific advancement as well as economic development and financial returns," said Chris Silva, CEO of Allied Minds.
Under the terms of the agreement, the companies have jointly formed and funded Allied-Bristol Life Sciences LLC, which will support the research and development needed to take these early-stage opportunities from initial feasibility to preclinical candidacy. Allied Minds and Bristol-Myers Squibb together will form and fund new companies to conduct feasibility and full-phase discovery programs. Once a program succeeds in identifying a pre-clinical candidate, Bristol-Myers Squibb will have the option to acquire the company from Allied-Bristol Life Sciences LLC under preagreed terms.
Source: Bristol-Myers Squibb
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
